wherein X_5 is from 0 to 16 amino acids; X_4 is serine, isoleucine, or lysine; X_3 is serine or lysine; X_2 is leucine or lysine; and X_1 is glutamine, asparagine or tyrosine, and wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). –

C2

23. (Twice Amended) --A method of producing a prodrug, the method comprising the step of linking

C3

a therapeutically active drug and

a peptide comprising an amino acid sequence having a cleavage site specific for an enzyme having a proteolytic activity of prostate specific antigen, wherein the peptide is 20 or fewer amino acids in length, wherein the sequence comprises the amino acids

$$X_5X_4X_3X_2X_1,$$

wherein X_5 is from 0 to 16 amino acids; X_4 is serine, isoleucine, or lysine; X_3 is serine or lysine; X_2 is leucine or lysine; and X_1 is glutamine, asparagine or tyrosine, and wherein the linking of the peptide to the drug inhibits the therapeutic activity of the drug.—

C